Beyond platinum sensitivity: immune-engaging therapies and multidimensional treatment stratification in relapsed small-cell lung cancer
4 affiliations
- 1Department of Medical Oncology, The First Affiliated Hospital of Dalian Medical University
- 2Department of Medical Oncology, Ningxiang People’s Hospital
- 3The Clinical Skill Training Center of Dalian Medical University
- 4Department of Medical Oncology, Dandong First Hospital
Abstract
Although platinum sensitivity remains a convenient way to categorize relapsed small-cell lung cancer (SCLC), it no longer captures the full range of factors that may influence response to newer treatments. The interval to relapse still carries useful clinical information because it reflects the initial response, the pace of disease, and the emergence of resistance. It does not, however, identify whether a relapsed tumor can support checkpoint blockade, be efficiently recognized by a T-cell engager, or support delivery and respond to an antibody-drug conjugate (ADC). This Review considers treatment vulnerability through five interconnected features: lineage plasticity, antigen-presentation competence, T-cell function, surface-target availability, and susceptibility to the delivered payload. We integrate clinical and translational findings for DLL3-directed T-cell engagers, B7-H3-directed ADCs, and SEZ6-directed ADCs, emphasizing that resistance may arise from the target, the immune effector compartment, or the payload. We then introduce a Time-Immune-Target framework. Time represents relapse kinetics; Immune denotes the functional capacity to mount or redirect an antitumor immune response; and Target denotes the accessibility of a therapeutically relevant surface antigen. Prior therapy is superimposed on these dimensions as a record of evolutionary pressure. This proposal is intended to guide hypothesis development, not current treatment assignment. Its clinical value will need to be tested prospectively using serial tissue and blood sampling, imaging, and formal biomarker-by-treatment interaction analyses.
Related
- A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
- A data-driven stratification framework for physical fitness in junior high school students: a composite approach based on BMI and multidimensional data
- Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer
- The Pregnane X Receptor (PXR) contributes to phenotypic plasticity and modulates the sensitivity to targeted therapies in melanoma
- Nanoparticle polymeric micellar paclitaxel (pm-Pac), platinum, and sintilimab as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer: a phase II study
BibTeX
@article{sun2026beyond,
title = {{Beyond platinum sensitivity: immune-engaging therapies and multidimensional treatment stratification in relapsed small-cell lung cancer}},
author = {Yang Sun and Xutong Zhao and Jia Zhang and Qinghao Song and Miao Cheng and Ye Chen and Yuhan Liu and Wenyan Hou and Wanting Fu and Xu Zhang and Huanling Hao and Yi Zhao},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1999309},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1999309/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond platinum sensitivity: immune-engaging therapies and multidimensional treatment stratification in relapsed small-cell lung cancer
AU - Yang Sun
AU - Xutong Zhao
AU - Jia Zhang
AU - Qinghao Song
AU - Miao Cheng
AU - Ye Chen
AU - Yuhan Liu
AU - Wenyan Hou
AU - Wanting Fu
AU - Xu Zhang
AU - Huanling Hao
AU - Yi Zhao
PY - 2026
DA - 2026/10/28
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1999309
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1999309/full
AB - Although platinum sensitivity remains a convenient way to categorize relapsed small-cell lung cancer (SCLC), it no longer captures the full range of factors that may influence response to newer treatments. The interval to relapse still carries useful clinical information because it reflects the initial response, the pace of disease, and the emergence of resistance. It does not, however, identify whether a relapsed tumor can support checkpoint blockade, be efficiently recognized by a T-cell engager, or support delivery and respond to an antibody-drug conjugate (ADC). This Review considers treatment vulnerability through five interconnected features: lineage plasticity, antigen-presentation competence, T-cell function, surface-target availability, and susceptibility to the delivered payload. We integrate clinical and translational findings for DLL3-directed T-cell engagers, B7-H3-directed ADCs, and SEZ6-directed ADCs, emphasizing that resistance may arise from the target, the immune effector compartment, or the payload. We then introduce a Time-Immune-Target framework. Time represents relapse kinetics; Immune denotes the functional capacity to mount or redirect an antitumor immune response; and Target denotes the accessibility of a therapeutically relevant surface antigen. Prior therapy is superimposed on these dimensions as a record of evolutionary pressure. This proposal is intended to guide hypothesis development, not current treatment assignment. Its clinical value will need to be tested prospectively using serial tissue and blood sampling, imaging, and formal biomarker-by-treatment interaction analyses.
SN - 1664-3224
ER -